Ftse Mib
33.326,39
0,42%
DAX
18.329,60
0,68%
S&P 500
5.482,87
0,09%
NASDAQ
17.858,68
0,30%
Bitcoin
61.366,45
-0,40%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN) Notizie

ELVN

Enliven Therapeutics (ELVN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELVN
DataOraFonteTitoloSimboloCompagnia
18/06/202423:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELVNEnliven Therapeutics Inc
11/06/202400:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
29/05/202422:05GlobeNewswire Inc.Enliven Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELVNEnliven Therapeutics Inc
14/05/202422:05GlobeNewswire Inc.Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
11/04/202413:55GlobeNewswire Inc.Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid LeukemiaNASDAQ:ELVNEnliven Therapeutics Inc
09/04/202422:05GlobeNewswire Inc.Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of DirectorsNASDAQ:ELVNEnliven Therapeutics Inc
28/03/202421:05GlobeNewswire Inc.Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024NASDAQ:ELVNEnliven Therapeutics Inc
19/03/202413:30GlobeNewswire Inc.Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline UpdatesNASDAQ:ELVNEnliven Therapeutics Inc
14/03/202421:05GlobeNewswire Inc.Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
27/02/202422:05GlobeNewswire Inc.Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:ELVNEnliven Therapeutics Inc
21/02/202401:35Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
16/02/202422:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
15/02/202402:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELVNEnliven Therapeutics Inc
09/11/202322:05GlobeNewswire Inc.Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:ELVNEnliven Therapeutics Inc
10/08/202322:05GlobeNewswire Inc.Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:ELVNEnliven Therapeutics Inc
06/07/202322:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ELVNEnliven Therapeutics Inc
05/07/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELVNEnliven Therapeutics Inc
26/06/202312:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ELVNEnliven Therapeutics Inc
19/05/202322:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ELVNEnliven Therapeutics Inc
11/05/202322:05GlobeNewswire Inc.Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial ResultsNASDAQ:ELVNEnliven Therapeutics Inc
10/05/202315:46Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ELVNEnliven Therapeutics Inc
21/03/202321:08Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ELVNEnliven Therapeutics Inc
06/03/202323:19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ELVNEnliven Therapeutics Inc
06/03/202322:03Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ELVNEnliven Therapeutics Inc
01/03/202322:57Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ELVNEnliven Therapeutics Inc
23/02/202323:20GlobeNewswire Inc.Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 MillionNASDAQ:ELVNEnliven Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ELVN

La tua Cronologia

NASDAQ
FAOVX
Franklin Growth Allocati...
BIT
P1W4Q3
NLBNPIT1W4Q3 20991231 16...
BIT
F18299
Vontobel Financial Produ...
BIT
UC46BY
Unicredit Bank
BOV
BNBR3F
BANCO NORDESTE ON
NASDAQ
MACA
Moringa Acquisition
LSE
82BC
Investec Bnk 26
GATE
CHESSETH
Chess
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network